OSAKA, Japan, December 1, 2025 - Shionogi & Co., Ltd. (Head Office: Osaka, Japan; Chief Executive Officer: Isao Teshirogi, Ph.D.; hereafter "Shionogi") announced today that, as stated in its press release dated May 7, 2025, titled “Announcement of Agreement on Company Split (Simplified Absorption-Type Split) of Japan Tobacco Inc.’s Pharmaceutical Business and Acquisition of Shares of Akros Pharma Inc. by Shionogi Inc. (Making It a Subsidiary),” and in the update disclosed on September 25, 2025, titled “Notice Regarding Execution of Absorption-Type Company Split Agreement (Simplified Absorption-Type Split) for Business Succession,” Shionogi has completed the succession of Japan Tobacco Inc.’s pharmaceutical business and the acquisition of shares of Akros Pharma Inc. by Shionogi Inc.